Micot Presents MT200605 Preclinical and Phase I Data, Cites Positive Stroke Phase II Results

Micot presented nonclinical and healthy-volunteer Phase I data for MT200605 at MDS 2026 and referenced previously disclosed positive Phase II results in acute ischemic stroke, including a significant benefit at high dose and an exploratory more than 80% lower AKI incidence versus placebo.